4.4 Article

Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients

Journal

CEPHALALGIA
Volume 42, Issue 8, Pages 804-809

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/03331024211068074

Keywords

Headache disorders; secondary; COVID-19; post-COVID; migraine

Funding

  1. regional health administration (Gerencia Regional de Salud (GRS) Castilla y Leon) [2289/A/2020]

Ask authors/readers for more resources

The duration of headache during the acute phase of COVID-19 is 2 weeks, but approximately a fifth of patients experience persistent headache following a chronic daily pattern.
Background Headache is a frequent symptoms of coronavirus disease 2019 (COVID-19). Its long-term evolution remains unknown. We aim to evaluate the long-term duration of headache in patients that presented headache during the acute phase of COVID-19. Methods This is a post-hoc multicenter ambisective study including patients from six different third-level hospitals between 1 March and 27 April 2020. Patients completed 9 months of neurological follow-up. Results We included 905 patients. Their median age was 51 (IQR 45-65), 66.5% were female, and 52.7% had a prior history of primary headache. The median duration of headache was 14 (6-39) days; however, the headache persisted after 3 months in 19.0% (95% CI: 16.5-21.8%) and after 9 months in 16.0% (95% confidence interval: 13.7-18.7%). Headache intensity during the acute phase was associated with a more prolonged duration of headache (Hazard ratio 0.655; 95% confidence interval: 0.582-0.737). Conclusion The median duration of headache was 2 weeks, but in approximately a fifth of patients it became persistent and followed a chronic daily pattern.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Intercritical photophobia in the migraineous patient. Proposal for diagnostic criteria

F. Ly-Yang, V. Gomez-Calleja, P. Perez-Garcia, N. Gonzalez-Gomez, J. Porta-Etessam, E. Santos-Bueso

Summary: This article presents 30 clinical cases of photophobia and reviews the literature in order to establish diagnostic criteria for this condition. The results suggest that the underlying causes of photophobia may involve the intrinsically photosensitive retinal ganglion cells as well as neurochemical factors like calcitonin-related peptide and the pituitary activating peptide cyclase. The treatment for photophobia could potentially involve the use of monoclonal antibodies targeting calcitonin-related peptide and/or pituitary activating peptide cyclase.

NEUROLOGIA (2023)

Article Clinical Neurology

Consensus Clinical Guidance for Diagnosis and Management of Adult COVID-19 Encephalopathy Patients

Benedict D. Michael, Dean Walton, Erica Westenberg, David Garcia-Azorin, Bhagteshwar Singh, Arina A. Tamborska, M. Netravathi, Mashina Chomba, Greta K. Wood, Ava Easton, Omar K. Siddiqi, Thomas A. Jackson, Thomas A. Pollak, Timothy R. Nicholson, Shalini Nair, Gerome Breen, Kameshwar Prasad, Kiran T. Thakur, Sherry H. -Y. Chou, Erich Schmutzhard, Jennifer A. Frontera, Raimund Helbok, Alessandro Padovani, David K. Menon, Tom Solomon, Andrea S. Winkler

Summary: Encephalopathy is a common and challenging condition among hospitalized COVID-19 patients, which can have a negative impact on prognosis. This review provides practical guidance on the management of COVID-19 encephalopathy through consensus agreement of the Global COVID-19 Neuro Research Coalition, covering definition, epidemiology, pathophysiology, clinical assessment, investigation, and both acute and long-term management.

JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES (2023)

Article Clinical Neurology

Structural brain changes in patients with persistent headache after COVID-19 resolution

Alvaro Planchuelo-Gomez, David Garcia-Azorin, Angel L. Guerrero, Margarita Rodriguez, Santiago Aja-Fernandez, Rodrigo de Luis-Garcia

Summary: Patients with persistent headache after COVID-19 resolution show diverse changes in brain structure, including both gray matter and white matter alterations. Compared to individuals without headache, these patients have lower cortical gray matter volume and thickness, accompanied by impaired white matter fiber bundles. Compared to migraine patients, those with persistent headache after COVID-19 recovery exhibit higher cortical volume and thickness in certain brain regions, as well as lower subcortical volume. The study suggests that persistent headache after COVID-19 resolution could be considered an intermediate state between normality and migraine.

JOURNAL OF NEUROLOGY (2023)

Review Clinical Neurology

Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review

Edoardo Caronna, Thomas C. van den Hoek, Hayrunnisa Bolay, David Garcia-Azorin, Ana Beatriz Gago-Veiga, Massimiliano Valeriani, Tsubasa Takizawa, Karl Messlinger, Robert E. Shapiro, Peter J. Goadsby, Messoud Ashina, Cristina Tassorelli, Hans-Christoph Diener, Gisela M. Terwindt, Patricia Pozo-Rosich

Summary: This article summarizes the knowledge on the epidemiology, pathophysiology, and management of secondary headache associated with SARS-CoV-2 infection and vaccination, as well as their impact on primary headache disorders. It was found that headache is a common symptom of both acute and post-acute phase of SARS-CoV-2 infection, and specific effective therapeutic options are currently lacking. Headache attributed to SARS-CoV-2 vaccinations is also common, but its pathophysiology remains unclear. People with primary headache disorders are more likely to experience headache during the acute phase of COVID-19 and after vaccination.

CEPHALALGIA (2023)

Editorial Material Clinical Neurology

Virtual issue: COVID-19 and headache

Edoardo Caronna, Patricia Pozo-Rosich

HEADACHE (2023)

Review Clinical Neurology

Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials

Faraidoon Haghdoost, Francesca Puledda, David Garcia-Azorin, Eva-Maria Huessler, Roberta Messina, Patricia Pozo-Rosich

Summary: This study evaluated the efficacy of novel treatments targeting the calcitonin gene-related peptide pathway for the prevention of migraine. The results showed that these medications significantly reduced monthly migraine and headache days, and had higher responder rates compared to placebo.

CEPHALALGIA (2023)

Article Clinical Neurology

Patterns of response to anti-calcitonin gene-related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome

Marta Torres-Ferrus, Victor J. J. Gallardo, Alicia Alpuente, Edoardo Caronna, Eulalia Gine-Cipres, Patricia Pozo-Rosich

Summary: This study examines the patterns of response to anti-CGRP MAbs in migraine patients during the first 6 months of treatment and its association with baseline clinical characteristics. The initial response to anti-CGRP MAbs varies among patients, and persistence of anxiety and depression may affect treatment response at 6 months.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Review Clinical Neurology

Headache as a COVID-19 onset symptom or Post-COVID symptom according to the SARS-CoV-2 Variant

Cesar Fernandez-de-Las-Penas, Maria L. Cuadrado, Victor Gomez-Mayordomo, David Garcia-Azorin, Lars Arendt-Nielsen

Summary: This article analyzes the differences in the prevalence of headache as an onset symptom and in post-COVID headache among the different SARS-CoV-2 variants (historical strain, Alpha, Delta, and Omicron) and discusses the different pathophysiological mechanisms by which SARS-CoV-2 infection may cause headache.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2023)

Article Clinical Neurology

Evaluating the Impact of a Training Program in Shared Decision-Making for Neurologists Treating People with Migraine

J. Porta-Etessam, S. Santos-Lasaosa, J. Rodriguez-Vico, M. Nunez, A. Ciudad, S. Diaz-Cerezo, M. Comellas, F. J. Perez-Sadaba, L. Lizan, A. L. Guerrero-Peral

Summary: Shared decision-making (SDM) training for neurologists in migraine care does not significantly impact patients’ decisional conflict and patient-physician relationship. However, physicians reported greater satisfaction and confidence in communicating with patients after the training.

NEUROLOGY AND THERAPY (2023)

Article Clinical Neurology

Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study

Alicia Alpuente, Anna Torre-Sune, Edoardo Caronna, Eulalia Gine-Cipres, Marta Torres-Ferrus, Patricia Pozo-Rosich

Summary: This study evaluated the impact of basal accompanying symptoms on anti-CGRP monoclonal antibodies treatment response and their evolution after six months of treatment in migraine patients. The results showed that the occurrence rates of accompanying symptoms decreased more in patients with a better response. The baseline photophobia ratio was positively correlated with the response rate between three and six months.

CEPHALALGIA (2023)

Article Clinical Neurology

Long-term outcomes of nummular headache: A series of 168 patients and 1198 patient-years of follow-up

Cristina Garcia-Iglesias, Ana Gonzalez-Celestino, Alvaro Sierra Mencia, Yesica Gonzalez Osorio, Andrea Recio Garcia, Cristina Martinez-Badillo, Ana Echavarria Iniguez, Berta Varona-Galan, David Garcia-Azorin, Angel Luis Guerrero-Peral

Summary: The long-term outcomes of nummular headache (NH) are generally positive, with a substantial number of patients experiencing inactive NH after a median follow-up period of 6.7 years. Preventive treatment is required by the majority of patients, but most of them respond well to the treatment. For patients with persistent symptoms, the frequency of headaches is lower.

CEPHALALGIA (2023)

Review Clinical Neurology

Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data

Carmen Sanchez-Rodriguez, Ana Beatriz Gago-Veiga, David Garcia-Azorin, Angel Luis Guerrero-Peral, Alicia Gonzalez-Martinez

Summary: This review summarizes the latest research findings on predictors of response to anti-CGRP therapies in patients with chronic migraine. The study suggests that migraine features (such as unilateral pain and positive triptan response) and chronic features (such as daily headache or medication overuse) may be linked to elevated baseline serum anti-CGRP levels.

CURRENT PAIN AND HEADACHE REPORTS (2023)

Article Clinical Neurology

Migraine worsening after COVID-19 and COVID-19 vaccination: Are we facing a nocebo effect?

Laura Melgarejo, Edoardo Caronna, Joana Rosell-Mirmi, Iker Elosua-Bayes, Alicia Alpuente, Marta Torres-Ferrus, Victor J. Gallardo, Patricia Pozo-Rosich

Summary: This study aimed to investigate the link between COVID-19 and COVID-19 vaccination with migraine worsening. The findings suggest that the infection and vaccination have a negligible role in migraine worsening and there may be a presence of a nocebo effect.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Review Biochemistry & Molecular Biology

Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review

Tsubasa Takizawa, Keiko Ihara, Shunsuke Uno, Seiya Ohtani, Narumi Watanabe, Noboru Imai, Jin Nakahara, Satoko Hori, David Garcia-Azorin, Paolo Martelletti

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2023)

Article Anesthesiology

Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study

Alicia Gonzalez-Martinez, Ancor Sanz-Garcia, David Garcia-Azorin, Jaime Rodriguez-Vico, Alex Jaimes, Andrea Gomez Garcia, Javier Casas-Limon, Javier Diaz de Teran, Maria Sastre-Real, Javier Membrilla, German Latorre, Carlos Calle de Miguel, Sendoa Gil Luque, Cristina Trevino-Peinado, Sonia Quintas, Patricia Heredia, Ana Echavarria-Iniguez, Angel Guerrero-Peral, Alvaro Sierra, Nuria Gonzalez-Garcia, Jesus Porta-Etessam, Ana Beatriz Gago-Veiga

Summary: This study evaluated the clinical characteristics, effectiveness, and tolerability of preventive anti-CGRP mAbs in the elderly. The results showed that anti-CGRP mAbs can effectively reduce the number of headaches in elderly patients with migraine, and their safety is similar to that of younger patients. In elderly patients, the diagnosis of episodic migraine and a lower baseline number of headaches were associated with a response to anti-CGRP mAbs.

PAIN MEDICINE (2023)

No Data Available